Quantitative Bias Analysis in Regulatory Settings.

Area of Science:

• Pharmacovigilance and Drug Safety
• Biostatistics
• Regulatory Science

Background:

• Nonrandomized studies are crucial for US Food and Drug Administration (FDA) postmarket surveillance.
• These studies often rely on imperfect data, introducing potential systematic errors and inaccurate inferences.
• Addressing uncertainty and bias is critical for reliable regulatory decision-making.

Purpose of the Study:

• To develop and implement analytic methods for quantifying uncertainty and bias in postmarket surveillance data.
• To support the FDA's regulatory decision-making processes by improving the accuracy of inferences from real-world evidence.
• To foster a collaborative project focused on advancing quantitative bias analysis tools.

Main Methods:

• Defining "quantitative bias analysis" as methods to estimate the direction, magnitude, and uncertainty of systematic errors.
• Developing tools to quantitatively assess uncertainties in postmarket surveillance studies.
• Implementing these methods within the FDA's regulatory framework.

Main Results:

• The collaborative project has made progress in developing quantitative bias analysis tools.
• The rationale and future directions for these tools have been outlined.
• The project aims to enhance the FDA's ability to handle imperfect data in regulatory science.

Conclusions:

• Quantitative bias analysis is essential for robust postmarket surveillance by the FDA.
• Developing and implementing these methods improves the reliability of regulatory decisions.
• Continued development and application of these tools are vital for public health protection.